Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 4/2016

Open Access 01-07-2016 | SSIEM 2015

From structural biology to designing therapy for inborn errors of metabolism

Author: Wyatt W. Yue

Published in: Journal of Inherited Metabolic Disease | Issue 4/2016

Login to get access

Abstract

At the SSIEM Symposium in Istanbul 2010, I presented an overview of protein structural approaches in the study of inborn errors of metabolism (Yue and Oppermann 2011). Five years on, the field is going strong with new protein structures, uncovered catalytic functions and novel chemical matters for metabolic enzymes, setting the stage for the next generation of drug discovery. This article aims to update on recent advances and lessons learnt on inborn errors of metabolism via the protein-centric approach, citing examples of work from my group, collaborators and co-workers that cover diverse pathways of transsulfuration, cobalamin and glycogen metabolism. Taking into consideration that many inborn errors of metabolism result in the loss of enzyme function, this presentation aims to outline three key principles that guide the design of small molecule therapy in this technically challenging field: (1) integrating structural, biochemical and cell-based data to evaluate the wide spectrum of mutation-driven enzyme defects in stability, catalysis and protein-protein interaction; (2) studying multi-domain proteins and multi-protein complexes as examples from nature, to learn how enzymes are activated by small molecules; (3) surveying different regions of the enzyme, away from its active site, that can be targeted for the design of allosteric activators and inhibitors.
Literature
go back to reference Arakawa T, Ejima D, Kita Y, Tsumoto K (2006) Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764:1677–1687CrossRefPubMed Arakawa T, Ejima D, Kita Y, Tsumoto K (2006) Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764:1677–1687CrossRefPubMed
go back to reference Balmer C, Pandey AV, Rufenacht V et al (2014) Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat 35:27–35CrossRefPubMed Balmer C, Pandey AV, Rufenacht V et al (2014) Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat 35:27–35CrossRefPubMed
go back to reference Bartesaghi A, Merk A, Banerjee S et al (2015) 2.2 A resolution cryo-EM structure of beta-galactosidase in complex with a cell-permeant inhibitor. Science 348:1147–1151CrossRefPubMed Bartesaghi A, Merk A, Banerjee S et al (2015) 2.2 A resolution cryo-EM structure of beta-galactosidase in complex with a cell-permeant inhibitor. Science 348:1147–1151CrossRefPubMed
go back to reference Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James MN (2011) Crystal structure of beta-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. J Med Chem 54:1421–1429CrossRefPubMedPubMedCentral Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James MN (2011) Crystal structure of beta-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. J Med Chem 54:1421–1429CrossRefPubMedPubMedCentral
go back to reference Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14:681–691CrossRefPubMed Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14:681–691CrossRefPubMed
go back to reference Boyd RE, Lee G, Rybczynski P et al (2013) Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56:2705–2725CrossRefPubMed Boyd RE, Lee G, Rybczynski P et al (2013) Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56:2705–2725CrossRefPubMed
go back to reference Burda P, Schafer A, Suormala T et al (2015) Insights into severe 5,10-methylenetetrahydrofolate reductase deficiency: molecular genetic and enzymatic characterization of 76 patients. Hum Mutat 36:611–621CrossRefPubMed Burda P, Schafer A, Suormala T et al (2015) Insights into severe 5,10-methylenetetrahydrofolate reductase deficiency: molecular genetic and enzymatic characterization of 76 patients. Hum Mutat 36:611–621CrossRefPubMed
go back to reference Chaikuad A, Froese DS, Berridge G, von Delft F, Oppermann U, Yue WW (2011) Conformational plasticity of glycogenin and its maltosaccharide substrate during glycogen biogenesis. Proc Natl Acad Sci U S A 108:21028–21033CrossRefPubMedPubMedCentral Chaikuad A, Froese DS, Berridge G, von Delft F, Oppermann U, Yue WW (2011) Conformational plasticity of glycogenin and its maltosaccharide substrate during glycogen biogenesis. Proc Natl Acad Sci U S A 108:21028–21033CrossRefPubMedPubMedCentral
go back to reference Ebrahimi-Fakhari D, Saffari A, Wahlster L, et al (2016) Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. Brain 139:317–337 Ebrahimi-Fakhari D, Saffari A, Wahlster L, et al (2016) Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. Brain 139:317–337
go back to reference Forny P, Froese DS, Suormala T, Yue WW, Baumgartner MR (2014) Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency. Hum Mutat 35:1449–1458CrossRefPubMedPubMedCentral Forny P, Froese DS, Suormala T, Yue WW, Baumgartner MR (2014) Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency. Hum Mutat 35:1449–1458CrossRefPubMedPubMedCentral
go back to reference Froese DS, Gravel RA (2010) Genetic disorders of vitamin B12 metabolism: eight complementation groups — eight genes. Expert Rev Mol Med 12:e37 Froese DS, Gravel RA (2010) Genetic disorders of vitamin B12 metabolism: eight complementation groups — eight genes. Expert Rev Mol Med 12:e37
go back to reference Froese DS, Kochan G, Muniz JR et al (2010) Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation. J Biol Chem 285:38204–38213CrossRefPubMedPubMedCentral Froese DS, Kochan G, Muniz JR et al (2010) Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation. J Biol Chem 285:38204–38213CrossRefPubMedPubMedCentral
go back to reference Froese DS, Krojer T, Wu X et al (2012) Structure of MMACHC reveals an arginine-rich pocket and a domain-swapped dimer for its B12 processing function. Biochemistry 51:5083–5090CrossRefPubMed Froese DS, Krojer T, Wu X et al (2012) Structure of MMACHC reveals an arginine-rich pocket and a domain-swapped dimer for its B12 processing function. Biochemistry 51:5083–5090CrossRefPubMed
go back to reference Froese DS, Forouhar F, Tran TH et al (2013) Crystal structures of malonyl-coenzyme A decarboxylase provide insights into its catalytic mechanism and disease-causing mutations. Structure 21:1182–1192CrossRefPubMedPubMedCentral Froese DS, Forouhar F, Tran TH et al (2013) Crystal structures of malonyl-coenzyme A decarboxylase provide insights into its catalytic mechanism and disease-causing mutations. Structure 21:1182–1192CrossRefPubMedPubMedCentral
go back to reference Froese DS, Kopec J, Fitzpatrick F et al (2015a) Structural insights into the MMACHC-MMADHC protein complex involved in vitamin B12 trafficking. J Biol Chem 290:29167–29177CrossRefPubMedPubMedCentral Froese DS, Kopec J, Fitzpatrick F et al (2015a) Structural insights into the MMACHC-MMADHC protein complex involved in vitamin B12 trafficking. J Biol Chem 290:29167–29177CrossRefPubMedPubMedCentral
go back to reference Froese DS, Michaeli A, McCorvie TJ et al (2015b) Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Hum Mol Genet 24:5667–5676CrossRefPubMedPubMedCentral Froese DS, Michaeli A, McCorvie TJ et al (2015b) Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Hum Mol Genet 24:5667–5676CrossRefPubMedPubMedCentral
go back to reference Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol 18:1521–1526CrossRefPubMedPubMedCentral Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol 18:1521–1526CrossRefPubMedPubMedCentral
go back to reference Jaffe EK, Lawrence SH (2012) Allostery and the dynamic oligomerization of porphobilinogen synthase. Arch Biochem Biophys 519:144–153CrossRefPubMed Jaffe EK, Lawrence SH (2012) Allostery and the dynamic oligomerization of porphobilinogen synthase. Arch Biochem Biophys 519:144–153CrossRefPubMed
go back to reference Jaffe EK, Stith L, Lawrence SH, Andrake M, Dunbrack RL Jr (2013) A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys 530:73–82CrossRefPubMedPubMedCentral Jaffe EK, Stith L, Lawrence SH, Andrake M, Dunbrack RL Jr (2013) A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys 530:73–82CrossRefPubMedPubMedCentral
go back to reference Jorge-Finnigan A, Brasil S, Underhaug J et al (2013) Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Hum Mol Genet 22:3680–3689CrossRefPubMedPubMedCentral Jorge-Finnigan A, Brasil S, Underhaug J et al (2013) Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Hum Mol Genet 22:3680–3689CrossRefPubMedPubMedCentral
go back to reference Kakhlon O, Glickstein H, Feinstein N et al (2013) Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase. J Neurochem 127:101–113PubMed Kakhlon O, Glickstein H, Feinstein N et al (2013) Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase. J Neurochem 127:101–113PubMed
go back to reference Kang TS, Stevens RC (2009) Structural aspects of therapeutic enzymes to treat metabolic disorders. Hum Mutat 30:1591–1610CrossRefPubMed Kang TS, Stevens RC (2009) Structural aspects of therapeutic enzymes to treat metabolic disorders. Hum Mutat 30:1591–1610CrossRefPubMed
go back to reference Landon MR, Lieberman RL, Hoang QQ et al (2009) Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 23:491–500CrossRefPubMed Landon MR, Lieberman RL, Hoang QQ et al (2009) Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 23:491–500CrossRefPubMed
go back to reference Makley LN, McMenimen KA, DeVree BT et al (2015) Pharmacological chaperone for alpha-crystallin partially restores transparency in cataract models. Science 350:674–677CrossRefPubMed Makley LN, McMenimen KA, DeVree BT et al (2015) Pharmacological chaperone for alpha-crystallin partially restores transparency in cataract models. Science 350:674–677CrossRefPubMed
go back to reference Marugan JJ, Zheng W, Ferrer M et al (2010) Discovery, SAR, and biological evaluation of a non-inhibitory chaperone for acid alpha glucosidase. In Probe Reports from the NIH Molecular Libraries Program Bethesda (MD) Marugan JJ, Zheng W, Ferrer M et al (2010) Discovery, SAR, and biological evaluation of a non-inhibitory chaperone for acid alpha glucosidase. In Probe Reports from the NIH Molecular Libraries Program Bethesda (MD)
go back to reference McCorvie TJ, Timson DJ (2013) In silico prediction of the effects of mutations in the human UDP-galactose 4′-epimerase gene: towards a predictive framework for type III galactosemia. Gene 524:95–104CrossRefPubMed McCorvie TJ, Timson DJ (2013) In silico prediction of the effects of mutations in the human UDP-galactose 4′-epimerase gene: towards a predictive framework for type III galactosemia. Gene 524:95–104CrossRefPubMed
go back to reference McCorvie TJ, Kopec J, Hyung SJ et al (2014) Inter-domain communication of human cystathionine beta-synthase: structural basis of S-adenosyl-L-methionine activation. J Biol Chem 289:36018–36030CrossRefPubMedPubMedCentral McCorvie TJ, Kopec J, Hyung SJ et al (2014) Inter-domain communication of human cystathionine beta-synthase: structural basis of S-adenosyl-L-methionine activation. J Biol Chem 289:36018–36030CrossRefPubMedPubMedCentral
go back to reference Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW (2014) Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 37:505–523CrossRefPubMed Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW (2014) Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 37:505–523CrossRefPubMed
go back to reference Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23:1138–1148CrossRefPubMed Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23:1138–1148CrossRefPubMed
go back to reference Patel D, Kopec J, Fitzpatrick F, McCorvie TJ, Yue WW (2016) Structural basis for ligand-dependent dimerization of phenylalanine hydroxylase regulatory domain. Sci Rep 6:23748. doi:10.1038/srep23748 Patel D, Kopec J, Fitzpatrick F, McCorvie TJ, Yue WW (2016) Structural basis for ligand-dependent dimerization of phenylalanine hydroxylase regulatory domain. Sci Rep 6:23748. doi:10.​1038/​srep23748
go back to reference Patnaik S, Zheng W, Choi JH et al (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem 55:5734–5748CrossRefPubMedPubMedCentral Patnaik S, Zheng W, Choi JH et al (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem 55:5734–5748CrossRefPubMedPubMedCentral
go back to reference Pederson BA, Turnbull J, Epp JR et al (2013) Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol 74:297–300PubMedPubMedCentral Pederson BA, Turnbull J, Epp JR et al (2013) Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol 74:297–300PubMedPubMedCentral
go back to reference Pey AL, Majtan T, Sanchez-Ruiz JM, Kraus JP (2013) Human cystathionine beta-synthase (CBS) contains two classes of binding sites for S-adenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM. Biochem J 449:109–121CrossRefPubMed Pey AL, Majtan T, Sanchez-Ruiz JM, Kraus JP (2013) Human cystathionine beta-synthase (CBS) contains two classes of binding sites for S-adenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM. Biochem J 449:109–121CrossRefPubMed
go back to reference Porto C, Ferrara MC, Meli M et al (2012) Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther 20:2201–2211CrossRefPubMedPubMedCentral Porto C, Ferrara MC, Meli M et al (2012) Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther 20:2201–2211CrossRefPubMedPubMedCentral
go back to reference Riemersma M, Froese DS, van Tol W et al (2015) Human ISPD Is a cytidyltransferase required for dystroglycan o-mannosylation. Chem Biol 22:1643–1652CrossRefPubMed Riemersma M, Froese DS, van Tol W et al (2015) Human ISPD Is a cytidyltransferase required for dystroglycan o-mannosylation. Chem Biol 22:1643–1652CrossRefPubMed
go back to reference Santos-Sierra S, Kirchmair J, Perna AM et al (2012) Novel pharmacological chaperones that correct phenylketonuria in mice. Hum Mol Genet 21:1877–1887CrossRefPubMed Santos-Sierra S, Kirchmair J, Perna AM et al (2012) Novel pharmacological chaperones that correct phenylketonuria in mice. Hum Mol Genet 21:1877–1887CrossRefPubMed
go back to reference Schiffmann R (2015) The consequences of genetic and pharmacologic reduction in sphingolipid synthesis. J Inherit Metab Dis 38:77–84CrossRefPubMed Schiffmann R (2015) The consequences of genetic and pharmacologic reduction in sphingolipid synthesis. J Inherit Metab Dis 38:77–84CrossRefPubMed
go back to reference Shafqat N, Kavanagh KL, Sass JO et al (2013) A structural mapping of mutations causing succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency. J Inherit Metab Dis 36:983–987CrossRefPubMedPubMedCentral Shafqat N, Kavanagh KL, Sass JO et al (2013) A structural mapping of mutations causing succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency. J Inherit Metab Dis 36:983–987CrossRefPubMedPubMedCentral
go back to reference Studer RA, Dessailly BH, Orengo CA (2013) Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochem J 449:581–594CrossRefPubMed Studer RA, Dessailly BH, Orengo CA (2013) Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochem J 449:581–594CrossRefPubMed
go back to reference Su XD, Zhang H, Terwilliger TC, Liljas A, Xiao J, Dong Y (2015) Protein crystallography from the perspective of technology developments. Crystallogr Rev 21:122–153CrossRefPubMedPubMedCentral Su XD, Zhang H, Terwilliger TC, Liljas A, Xiao J, Dong Y (2015) Protein crystallography from the perspective of technology developments. Crystallogr Rev 21:122–153CrossRefPubMedPubMedCentral
go back to reference Suzuki Y, Ogawa S, Sakakibara Y (2009) Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Med Chem 3:7–19 Suzuki Y, Ogawa S, Sakakibara Y (2009) Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Med Chem 3:7–19
go back to reference Torreblanca R, Lira-Navarrete E, Sancho J, Hurtado-Guerrero R (2012) Structural and mechanistic basis of the interaction between a pharmacological chaperone and human phenylalanine hydroxylase. Chembiochem 13:1266–1269CrossRefPubMed Torreblanca R, Lira-Navarrete E, Sancho J, Hurtado-Guerrero R (2012) Structural and mechanistic basis of the interaction between a pharmacological chaperone and human phenylalanine hydroxylase. Chembiochem 13:1266–1269CrossRefPubMed
go back to reference Wettstein S, Underhaug J, Perez B et al (2015) Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur J Hum Genet 23:302–309CrossRefPubMed Wettstein S, Underhaug J, Perez B et al (2015) Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur J Hum Genet 23:302–309CrossRefPubMed
go back to reference Yoon H, Knight SA, Pandey A et al (2014) Frataxin-bypassing Isu1: characterization of the bypass activity in cells and mitochondria. Biochem J 459:71–81CrossRefPubMedPubMedCentral Yoon H, Knight SA, Pandey A et al (2014) Frataxin-bypassing Isu1: characterization of the bypass activity in cells and mitochondria. Biochem J 459:71–81CrossRefPubMedPubMedCentral
go back to reference Yue WW, Oppermann U (2011) High-throughput structural biology of metabolic enzymes and its impact on human diseases. J Inherit Metab Dis 34:575–581CrossRefPubMed Yue WW, Oppermann U (2011) High-throughput structural biology of metabolic enzymes and its impact on human diseases. J Inherit Metab Dis 34:575–581CrossRefPubMed
go back to reference Yue WW, Froese DS, Brennan PE (2014) The role of protein structural analysis in the next generation sequencing era. Top Curr Chem 336:67–98CrossRefPubMed Yue WW, Froese DS, Brennan PE (2014) The role of protein structural analysis in the next generation sequencing era. Top Curr Chem 336:67–98CrossRefPubMed
go back to reference Zeqiraj E, Tang X, Hunter RW et al (2014) Structural basis for the recruitment of glycogen synthase by glycogenin. Proc Natl Acad Sci U S A 111:E2831–2840CrossRefPubMedPubMedCentral Zeqiraj E, Tang X, Hunter RW et al (2014) Structural basis for the recruitment of glycogen synthase by glycogenin. Proc Natl Acad Sci U S A 111:E2831–2840CrossRefPubMedPubMedCentral
go back to reference Zhang S, Roberts KM, Fitzpatrick PF (2014) Phenylalanine binding is linked to dimerization of the regulatory domain of phenylalanine hydroxylase. Biochemistry 53:6625–6627CrossRefPubMedPubMedCentral Zhang S, Roberts KM, Fitzpatrick PF (2014) Phenylalanine binding is linked to dimerization of the regulatory domain of phenylalanine hydroxylase. Biochemistry 53:6625–6627CrossRefPubMedPubMedCentral
go back to reference Zickermann V, Wirth C, Nasiri H et al (2015) Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. Science 347:44–49CrossRefPubMed Zickermann V, Wirth C, Nasiri H et al (2015) Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I. Science 347:44–49CrossRefPubMed
Metadata
Title
From structural biology to designing therapy for inborn errors of metabolism
Author
Wyatt W. Yue
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 4/2016
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9923-3

Other articles of this Issue 4/2016

Journal of Inherited Metabolic Disease 4/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.